Display options
Cite
Biylgi O, Karagöz B, Türken O, et al. CD4+CD25(high), CD8+CD28- cells and thyroid autoantibodies in breast cancer patients. Cent Eur J Immunol. 2014;39(3):338-44doi: 10.5114/ceji.2014.45945.
Biylgi, O., Karagöz, B., Türken, O., Gültepe, M., Özgün, A., Tunçel, T., Emirzeoğlu, L., Çelik, S., Müftüoğlu, T., & Gökhan Kandemir, E. (2014). CD4+CD25(high), CD8+CD28- cells and thyroid autoantibodies in breast cancer patients. Central-European journal of immunology, 39(3), 338-44. https://doi.org/10.5114/ceji.2014.45945
Biylgi, Oğuz, et al. "CD4+CD25(high), CD8+CD28- cells and thyroid autoantibodies in breast cancer patients." Central-European journal of immunology vol. 39,3 (2014): 338-44. doi: https://doi.org/10.5114/ceji.2014.45945
Biylgi O, Karagöz B, Türken O, Gültepe M, Özgün A, Tunçel T, Emirzeoğlu L, Çelik S, Müftüoğlu T, Gökhan Kandemir E. CD4+CD25(high), CD8+CD28- cells and thyroid autoantibodies in breast cancer patients. Cent Eur J Immunol. 2014;39(3):338-44. doi: 10.5114/ceji.2014.45945. Epub 2014 Oct 14. PMID: 26155145; PMCID: PMC4439998.
Copy Download .nbib Format: NLM
Share it on

Cent Eur J Immunol. 2014;39(3):338-44. doi: 10.5114/ceji.2014.45945. Epub 2014 Oct 14.

CD4+CD25(high), CD8+CD28- cells and thyroid autoantibodies in breast cancer patients.

Central-European journal of immunology

Oğuz Biylgi, Bülent Karagöz, Orhan Türken, Mustafa Gültepe, Alpaslan Özgün, Tolga Tunçel, Levent Emirzeoğlu, Serkan Çelik, Tuba Müftüoğlu, Emin Gökhan Kandemir

Affiliations

  1. Department of Medical Oncology, GATA Haydarpasa Hospital, Istanbul, Turkey.
  2. Department of Medical Oncology, Maltepe University, Istanbul, Turkey.
  3. Department of Biochemistry, GATA Haydarpasa Hospital, Istanbul, Turkey.
  4. Department of Medical Oncology, Memorial Hospital, Istanbul, Turkey.

PMID: 26155145 PMCID: PMC4439998 DOI: 10.5114/ceji.2014.45945

Abstract

AIM OF THE STUDY: To investigate the percentage of CD4+CD25(high) cells (including Treg cells) and CD8+CD28- cells in breast cancer patients with and without high levels of autoimmune thyroid antibodies.

MATERIAL AND METHODS: Thirty-five women with breast cancer (9 of them having high thyroid antibodies) and fourteen healthy subjects were enrolled in this study. Flow cytometry was used to count CD4+CD25(high) cells and CD8+CD28- suppressive cells (CD8 cell subtypes).

RESULTS: In the patient group, the percentage of CD28- cells in CD8+ lymphocytes were higher [67.50% (55.1180.33) vs. 51.56% (42.5766.38); p = 0.021] and the percentage of CD28+CD45RO- cells (memory cells) in CD8+ lymphocytes were lower than in the control group. CD4+CD25(high) cell percentage in CD4+ lymphocytes was elevated in the patient group [6.44% (4.528.74) vs. 2.97% (1.724.34); p < 0.001]. When the cytometric parameters were compared between patients (with high vs. normal thyroid antibodies), the distribution of CD8+ cell subgroups was also similar. CD4+CD25(high) cells among CD4+ lymphocytes were decreased in patients with high levels of thyroid antibodies [5.19% (3.426.17) vs. 6.99% (4.829.95); p = 0.043].

CONCLUSIONS: CD4+CD25(high) cells may play a role in autoimmunity of breast cancer patients, and may be a predictive marker. Advanced studies which evaluate the possible links between regulatory cells and autoimmunity should be established in cancer patients.

Keywords: Treg cells; autoimmunity; breast cancer; thyroid antibody

References

  1. Clin Exp Immunol. 2007 Mar;147(3):547-54 - PubMed
  2. Breast Cancer Res. 2003;5(5):R110-3 - PubMed
  3. Cancer Immunol Immunother. 2006 Sep;55(9):1064-71 - PubMed
  4. Scand J Immunol. 2006 Sep;64(3):211-8 - PubMed
  5. Oncol Rep. 2005 Nov;14(5):1269-73 - PubMed
  6. Cancer Immunol Immunother. 2003 Oct;52(10):599-607 - PubMed
  7. Anticancer Res. 2008 Mar-Apr;28(2A):779-84 - PubMed
  8. Cancer Immunol Immunother. 2004 Feb;53(2):73-8 - PubMed
  9. Clin Exp Immunol. 1975 Sep;21(3):362-75 - PubMed
  10. Ann Med. 1997 Jun;29(3):189-91 - PubMed
  11. Breast Cancer Res Treat. 2012 Jun;133(3):1169-77 - PubMed
  12. Ai Zheng. 2007 Jul;26(7):748-51 - PubMed
  13. Hum Immunol. 2008 Nov;69(11):781-9 - PubMed
  14. Hum Immunol. 2006 Jan-Feb;67(1-2):1-12 - PubMed
  15. Cancer Immunol Immunother. 2012 Jun;61(6):911-6 - PubMed
  16. Lab Invest. 1976 Jun;34(6):550-7 - PubMed
  17. J Transl Med. 2013 Dec 12;11:307 - PubMed
  18. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 - PubMed
  19. Head Neck. 2007 Feb;29(2):120-7 - PubMed
  20. Med Oncol. 2010 Mar;27(1):29-33 - PubMed
  21. Front Biosci. 2006 May 01;11:1234-43 - PubMed
  22. J Cancer Res Clin Oncol. 2012 Nov;138(11):1945-50 - PubMed
  23. Br J Cancer. 2007 Feb 26;96(4):617-22 - PubMed
  24. BMC Immunol. 2009 Jan 27;10:5 - PubMed
  25. Clin Ter. 2012 Nov;163(6):e401-4 - PubMed
  26. J Immunol. 2007 Oct 1;179(7):4323-34 - PubMed
  27. J Immunol. 2007 Jun 15;178(12):7649-57 - PubMed
  28. Immunol Lett. 2006 Feb 15;102(2):229-36 - PubMed
  29. Radiother Oncol. 2012 Jul;104(1):131-8 - PubMed
  30. Autoimmunity. 2014 May;47(3):201-11 - PubMed
  31. Endocrinology. 2007 Dec;148(12):5724-33 - PubMed

Publication Types